Applied Molecular Transport Inc.

Thornhill Therapeutics, Inc.

Khushdeep Mangat

Sean Dalziel

Randall J Mrsny

Tahir Mahmood

Derek Maclean

Sally Rhiannon Postlethwaite

Weijun Feng

James Andrew Whitney

Charles Olson

Amir Porat

Bittoo Kanwar

Rajendra Tandale

Hyojin Kim

Marvin Garovoy

Elizabeth Bhatt

John Koleng

Sally Postlethwaite

Kevin Yin

Described herein are cholix-IL-10 fusion proteins, and methods of use thereof, which can be characterized by a distinct response in an individual when administered. This distinct response can comprise changes in levels of one or more markers in the individual and/or co-localization of IL-10 in theof the individual. Further described herein, in some embodiments, are oral formulations of the cholix-IL-10 fusion proteins. Described herein are methods for the purification of an IL-10 delivery construct, including methods for refolding and enrichment, which can result in maintenance of a high percentage of the IL-10 delivery constructs in the biologically active dimer form. Described herein are oral formulations configured for site-specific release of a therapeutic protein in the small intestines or colon. In some cases, the therapeutic protein is in the form of a dimer, such as an IL-10 delivery construct capable of crossing the gut epithelium.

Compositions, formulations and interleukin production and purification

Growing community of inventors

Cambridge, MA, United States of America

Khushdeep Mangat